CEO, Thea Olesen

Master degree in law, LL.M., University of Copenhagen, 1992.

Managing Director of BioPorto A/S from October, 2005, and subsequently also of the subsidiary company BioPorto Diagnostics A/S.

Acted as a leading administrative employee from the year 2000 onwards at the founding of what is now BioPorto Diagnostics A/S, and played an active role in the acquisition of BioPorto Diagnostics A/S by BioPorto A/S as well as the launching of the latter on the stock exchange in 2004. Since joining as CEO in 2005, BioPorto has been focusing on the kidney injury diagnostic area, including the company’s development of NGAL as a kidney injury marker and the marketing of The NGAL Test ™.

Apart from the experience gained from the founding and development of BioPorto, previous experience is gained from managerial posts in medicotechnology and other branches, as well as a post as company lawyer for several years. Throughout the period various board positions are held, currently as a board member in Larix A/S and Olesens A/S.

CFO, Frank Harder

Has served as the Chief Financial Officer of BioPorto since 2007. Holds a Master Science degree in Forestry from the University of Copenhagen.

Has a solid background within the Life Sciences sector holding positions as a Director of Finance at Novo Nordisk from 1989-2000 and serving as the CFO of the biotech company Zymenex from 2000-2006.

Scientific Director, Lars Otto Uttenthal

B.M., B.Ch., M.A. (Animal Physiology), D.Phil. (Biochemistry), University of Oxford, M.R.C.P. (UK); Medical specialist in Endocrinology and Diabetes Mellitus; Formerly Research Fellow, Royal Postgraduate Medical School, University of London; Associate Professor of Biochemistry, Faculty of Medicine, University of Salamanca; Research Fellow, Cajal Institute of Neurobiology (Science Research Council), Madrid.

Joined the company in its first year and is inventor of several BioPorto patents and patent applications including those on the diagnosis of kidney disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL).